Outcome | SFT (n=48) | CAU (n=49) | SFT vs CAU | |||
---|---|---|---|---|---|---|
Estimate | Effect size | Estimate | Effect size | Effect size | p Value | |
CIS-Fatigue* | ||||||
Baseline | 46.4 | 46.4 | ||||
3 Months | 37.9 | −1.13 | 42.6 | −0.51 | −0.62 | <0.001 |
6 Months | 36.9 | −1.26 | 40.4 | −0.80 | −0.46 | 0.010 |
9 Months | 37.8 | −1.15 | 38.7 | −1.03 | −0.12 | 0.610 |
CIS-Total | ||||||
Baseline | 100.7 | 100.7 | ||||
3 Months | 83.5 | −0.97 | 93.4 | −0.41 | −0.56 | 0.001 |
6 Months | 81.0 | −1.11 | 88.6 | −0.68 | −0.43 | 0.010 |
9 Months | 82.1 | −1.05 | 84.4 | −0.91 | −0.13 | 0.531 |
FSS-Total | ||||||
Baseline | 5.51 | 5.51 | ||||
3 Months | 5.11 | −0.54 | 5.11 | −0.54 | ||
6 Months | 4.95 | −0.75 | 4.95 | −0.75 | ||
9 Months | 4.85 | −0.89 | 4.85 | −0.89 | ||
EQ-5D | ||||||
All time points | 0.83 | 0.83 | ||||
IBDQ-Total | ||||||
Baseline | 165.5 | 165.5 | ||||
3 Months | 173.3 | 0.34 | 166.7 | 0.06 | 0.29 | 0.020 |
6 Months | 174.6 | 0.40 | 171.0 | 0.24 | 0.15 | 0.241 |
9 Months | 174.2 | 0.38 | 176.1 | 0.46 | −0.08 | 0.635 |
SF-36 Physical* | ||||||
Baseline | 39.1 | 39.1 | ||||
3 Months | 44.8 | 0.69 | 42.5 | 0.40 | 0.29 | 0.070 |
6 Months | 45.9 | 0.82 | 44.7 | 0.67 | 0.15 | 0.351 |
9 Months | 45.7 | 0.80 | 46.6 | 0.90 | −0.10 | 0.605 |
SF-36 Mental | ||||||
All time points | 45.9 | 41.9 | ||||
PSQI | ||||||
Baseline | 6.01 | 6.01 | ||||
3 Months | 5.63 | −0.13 | 5.63 | −0.13 | ||
6 Months | 5.48 | −0.18 | 5.48 | −0.18 | ||
9 Months | 5.38 | −0.21 | 5.38 | −0.21 |
CIS, Checklist Individual Strength; FSS, Fatigue Severity Scale; IBDQ, Inflammatory Bowel Disease Questionnaire; PSQI, Pittsburgh Sleep Quality Index; SFT, solution-focused therapy group; CAU, care as usual group.
*Estimates at the mean of covariate age (40.12 years).